comparemela.com

Latest Breaking News On - Fera pharmaceuticals - Page 2 : comparemela.com

Patients With Serious Ophthalmologic Conditions Have Access to Phospholine Iodide®

Top GOP Rules staffer heading back to K Street- POLITICO

Nicox s Partner Fera Pharmaceuticals Obtains Orphan Drug Designation from the U S FDA for Naproxcinod for the Treatment of Sickle Cell Disease

Press ReleaseNicox's Partner Fera Pharmaceuticals Obtains Orphan Drug Designation from the U.S. FDA for Naproxcinod for the Treatment of Sickle Cell DiseaseMarch 2nd, 2022 - release at 7:30 am CET Sophia

Global Anti-Glaucoma Drug Market Top Manufacturers, Latest Innovation with Trends and Forecast 2021

Global Anti-Glaucoma Drug Market Top Manufacturers, Latest Innovation with Trends and Forecast 2021
pharmiweb.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pharmiweb.com Daily Mail and Mail on Sunday newspapers.

Nicox Provides Fourth Quarter 2020 Business Update and Financial Highlights

Nicox Provides Fourth Quarter 2020 Business Update and Financial Highlights Nicox Provides Fourth Quarter 2020 Business Update and Financial Highlights Initiated two large clinical trials: Denali, the second Phase 3 of NCX 470 in glaucoma, and Mississippi, a Phase 2b of NCX 4251 in blepharitis Phase 3 clinical trial of ZERVIATE in allergic conjunctivitis initiated by partner Ocumension Therapeutics in China U.S. prescriptions for VYZULTA TM by 56% over Q3 2020 Q4 2020 net revenue of €5.8 million, full year 2020 net revenue of €8.9 million and cash of €47.8 million at December 31, 2020 January 20, 2021 - release at 7:30 am CET Sophia Antipolis, France Nicox SA (Euronext Paris: FR0013018124, COX), an international ophthalmology company, today provided a business update and financial highlights for Q4 2020 for Nicox SA and its subsidiaries (the Nicox Group ), as well as key expected value-inflection milestones in 2021.

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.